"nct_id","nlm_download_date_description","study_first_submitted_date","results_first_submitted_date","disposition_first_submitted_date","last_update_submitted_date","study_first_submitted_qc_date","study_first_posted_date","study_first_posted_date_type","results_first_submitted_qc_date","results_first_posted_date","results_first_posted_date_type","disposition_first_submitted_qc_date","disposition_first_posted_date","disposition_first_posted_date_type","last_update_submitted_qc_date","last_update_posted_date","last_update_posted_date_type","start_month_year","start_date_type","start_date","verification_month_year","verification_date","completion_month_year","completion_date_type","completion_date","primary_completion_month_year","primary_completion_date_type","primary_completion_date","target_duration","study_type","acronym","baseline_population","brief_title","official_title","overall_status","last_known_status","phase","enrollment","enrollment_type","source","limitations_and_caveats","number_of_arms","number_of_groups","why_stopped","has_expanded_access","expanded_access_type_individual","expanded_access_type_intermediate","expanded_access_type_treatment","has_dmc","is_fda_regulated_drug","is_fda_regulated_device","is_unapproved_device","is_ppsd","is_us_export","biospec_retention","biospec_description","ipd_time_frame","ipd_access_criteria","ipd_url","plan_to_share_ipd","plan_to_share_ipd_description","created_at","updated_at","source_class","delayed_posting","expanded_access_nctid","expanded_access_status_for_nctid","fdaaa801_violation","baseline_type_units_analyzed","patient_registry"
"NCT00709735",NA,"2008-06-30","2012-05-01",NA,"2017-04-06","2008-07-02","2008-07-03","ESTIMATED","2017-04-06","2017-04-10","ACTUAL",NA,NA,NA,"2017-04-06","2017-04-10","ACTUAL","2007-05","ACTUAL","2007-05-31","2017-04","2017-04-30","2010-08","ACTUAL","2010-08-31","2010-02","ACTUAL","2010-02-28",NA,"INTERVENTIONAL",NA,"All randomized participants who completed the study.","A Psychophysiologic Study of Weakening Traumatic Combat Memories With Post-Reactivation Propranolol","A Psychophysiologic Study of Weakening Traumatic Combat Memories With Post-Reactivation Propranolol","COMPLETED",NA,"PHASE4",23,"ACTUAL","Massachusetts General Hospital","Small participant sample due to recruitment difficulties.",2,NA,NA,"f",NA,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-15 00:32:43.143115","2024-09-15 00:32:43.143115","OTHER",NA,NA,NA,NA,NA,NA
"NCT01364298",NA,"2011-05-31","2013-07-30",NA,"2013-12-18","2011-06-01","2011-06-02","ESTIMATED","2013-12-18","2014-02-06","ESTIMATED",NA,NA,NA,"2013-12-18","2014-02-06","ESTIMATED","2011-04",NA,"2011-04-30","2013-12","2013-12-31","2012-07","ACTUAL","2012-07-31","2012-07","ACTUAL","2012-07-31",NA,"INTERVENTIONAL",NA,"Safety population included all the randomized participants who received at least one dose of study drug.","Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management","Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain","COMPLETED",NA,"PHASE4",353,"ACTUAL","Merck KGaA, Darmstadt, Germany",NA,2,NA,NA,"f",NA,NA,NA,"t",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-15 00:32:43.143115","2024-09-15 00:32:43.143115","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT03122119",NA,"2017-04-16","2023-03-18",NA,"2023-04-26","2017-04-19","2017-04-20","ACTUAL","2023-04-26","2023-04-28","ACTUAL",NA,NA,NA,"2023-04-26","2023-04-28","ACTUAL","2017-05-01","ACTUAL","2017-05-01","2023-04","2023-04-30","2022-09-01","ACTUAL","2022-09-01","2020-03-01","ACTUAL","2020-03-01",NA,"INTERVENTIONAL",NA,"not different from the assignment in participant flow","Effectiveness of Ultrasound Guided Platelet Rich Plasma Injections in the Sacroiliac Joint","Effectiveness of Ultrasound Guided Platelet Rich Plasma Injections in the Sacroiliac Joint to Relieve Low Back Pain","COMPLETED",NA,"PHASE4",51,"ACTUAL","Star Spine and Sport",NA,1,NA,NA,"f",NA,NA,NA,"t","t","f",NA,NA,"f",NA,NA,NA,NA,NA,"NO",NA,"2024-09-16 11:36:05.560137","2024-09-16 11:36:05.560137","OTHER",NA,NA,NA,NA,NA,NA
"NCT03324880",NA,"2017-10-10","2023-05-03",NA,"2023-05-12","2017-10-24","2017-10-30","ACTUAL","2023-05-12","2023-06-09","ACTUAL",NA,NA,NA,"2023-05-12","2023-06-09","ACTUAL","2018-01-24","ACTUAL","2018-01-24","2023-05","2023-05-31","2022-05-19","ACTUAL","2022-05-19","2022-05-19","ACTUAL","2022-05-19",NA,"INTERVENTIONAL",NA,"Safety Analysis Set included all participants in the Intention-to-Treat (ITT) Set who took at least 1 dose of investigational product (study drug or placebo).","A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE)","A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]","COMPLETED",NA,"PHASE4",93,"ACTUAL","Takeda",NA,2,NA,NA,"f",NA,NA,NA,"f","t","f",NA,NA,NA,NA,NA,NA,"IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.","https://vivli.org/ourmember/takeda/","YES","Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.","2024-09-16 11:36:05.560137","2024-09-16 11:36:05.560137","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT01453374",NA,"2011-10-13","2015-05-21",NA,"2015-06-19","2011-10-13","2011-10-17","ESTIMATED","2015-06-19","2015-07-13","ESTIMATED",NA,NA,NA,"2015-06-19","2015-07-13","ESTIMATED","2011-01",NA,"2011-01-31","2015-06","2015-06-30","2014-05","ACTUAL","2014-05-31","2014-05","ACTUAL","2014-05-31",NA,"INTERVENTIONAL",NA,"All subjects who received at least 1 injection of VIVITROL","A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration","A Phase 4, Pilot, Open-label Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration","COMPLETED",NA,"PHASE4",27,"ACTUAL","Alkermes, Inc.","The outcome measure of opioid dependence was not analyzed.",1,NA,NA,"f",NA,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-15 00:32:43.143115","2024-09-15 00:32:43.143115","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT02007278",NA,"2013-12-05","2017-02-23",NA,"2017-04-13","2013-12-05","2013-12-10","ESTIMATED","2017-04-13","2017-07-11","ACTUAL",NA,NA,NA,"2017-04-13","2017-07-11","ACTUAL","2014-01-03","ACTUAL","2014-01-03","2017-04","2017-04-30","2016-02-22","ACTUAL","2016-02-22","2016-02-22","ACTUAL","2016-02-22",NA,"INTERVENTIONAL","GLOBE","Randomized set","Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride","Glycemic Excursions in Type 2 Diabetic Patients Treated With Vildagliptin and Metformin (GalvusMet) Versus Glimepiride and Metformin","COMPLETED",NA,"PHASE4",40,"ACTUAL","Novartis",NA,2,NA,NA,"f",NA,NA,NA,"f","f","f",NA,NA,NA,NA,NA,NA,NA,NA,"UNDECIDED",NA,"2024-09-15 12:18:05.040516","2024-09-15 12:18:05.040516","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT00048165",NA,"2002-10-24","2016-05-04",NA,"2016-05-04","2002-10-24","2002-10-25","ESTIMATED","2016-05-04","2016-06-13","ESTIMATED",NA,NA,NA,"2016-05-04","2016-06-13","ESTIMATED","1999-08",NA,"1999-08-31","2016-05","2016-05-31","2002-08","ACTUAL","2002-08-31","2002-08","ACTUAL","2002-08-31",NA,"INTERVENTIONAL",NA,"The randomized population included all participants who were randomized into the study, whether they received the study drug or not.","A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation","A Double-Blind, Placebo -Controlled, Randomized Study to Assess the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation.","COMPLETED",NA,"PHASE4",434,"ACTUAL","Hoffmann-La Roche",NA,2,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-15 12:18:05.040516","2024-09-15 12:18:05.040516","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT03810235",NA,"2019-01-07","2020-07-09",NA,"2022-10-28","2019-01-16","2019-01-18","ACTUAL","2020-08-19","2020-09-07","ACTUAL",NA,NA,NA,"2022-10-28","2022-11-01","ACTUAL","2019-02-15","ACTUAL","2019-02-15","2022-10","2022-10-31","2019-11-30","ACTUAL","2019-11-30","2019-09-09","ACTUAL","2019-09-09",NA,"INTERVENTIONAL","OBLido","baseline characteristics for participants who completed the study","The OBstetric Lidocaine Patch (OBLido) Trial","Transdermal Lidocaine Patch for Post-Cesarean Pain Control for Women With Obesity: a Single-blind Randomized Controlled Trial","COMPLETED",NA,"PHASE4",66,"ACTUAL","University of Wisconsin, Madison",NA,2,NA,NA,"f",NA,NA,NA,"t","t","f",NA,NA,"t",NA,NA,NA,NA,NA,"NO",NA,"2024-09-15 12:18:05.040516","2024-09-15 12:18:05.040516","OTHER",NA,NA,NA,NA,NA,NA
"NCT01473394",NA,"2011-11-14","2014-02-21",NA,"2014-02-21","2011-11-16","2011-11-17","ESTIMATED","2014-02-21","2014-04-03","ESTIMATED",NA,NA,NA,"2014-02-21","2014-04-03","ESTIMATED","2011-12",NA,"2011-12-31","2014-02","2014-02-28","2013-02","ACTUAL","2013-02-28","2013-02","ACTUAL","2013-02-28",NA,"INTERVENTIONAL",NA,"Safety population: All randomized participants who received at least 1 dose of double-blind investigational product.","Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder","A Double-blind, Placebo-controlled, Fixed-dose Study of Vilazodone in Patients With Major Depressive Disorder","COMPLETED",NA,"PHASE4",518,"ACTUAL","Forest Laboratories",NA,2,NA,NA,"f",NA,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-15 12:18:05.040516","2024-09-15 12:18:05.040516","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT00502853",NA,"2007-07-17","2014-07-16",NA,"2017-07-07","2007-07-17","2007-07-18","ESTIMATED","2015-03-10","2015-03-12","ESTIMATED",NA,NA,NA,"2017-07-07","2017-08-16","ACTUAL","2007-10-25","ACTUAL","2007-10-25","2017-06","2017-06-30","2010-07-23","ACTUAL","2010-07-23","2010-07-23","ACTUAL","2010-07-23",NA,"INTERVENTIONAL",NA,"Safety population: all participants who received any part of an infusion of study drug.","A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.","Pilot Study to Evaluate the Effect of Mabthera in Combination With MTX in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis.","COMPLETED",NA,"PHASE4",10,"ACTUAL","Hoffmann-La Roche",NA,1,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-15 12:24:53.847654","2024-09-15 12:24:53.847654","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT01180049",NA,"2010-08-09","2016-11-04",NA,"2019-05-17","2010-08-10","2010-08-11","ESTIMATED","2017-04-11","2017-05-19","ACTUAL",NA,NA,NA,"2019-05-17","2019-05-20","ACTUAL","2011-03","ACTUAL","2011-03-31","2019-05","2019-05-31","2018-06","ACTUAL","2018-06-30","2015-11","ACTUAL","2015-11-30",NA,"INTERVENTIONAL",NA,"The analysis was done on Intent-to-Treat (ITT) Population which included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or received a different drug dose from that to which they were randomized.","Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma","A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA","COMPLETED",NA,"PHASE4",101,"ACTUAL","Pfizer","Overall Survival was not collected for the intended duration as planned initially, no long term follow up was conducted according to amendment in protocol. Hence overall survival results were limited",2,NA,NA,"f",NA,NA,NA,"t",NA,NA,NA,NA,NA,NA,NA,NA,NA,"https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests","YES","Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.","2024-09-15 12:24:53.847654","2024-09-15 12:24:53.847654","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT06236113",NA,"2024-01-12","2024-02-16",NA,"2024-05-16","2024-01-23","2024-02-01","ACTUAL","2024-05-16","2024-05-21","ACTUAL",NA,NA,NA,"2024-05-16","2024-05-21","ACTUAL","2021-10-01","ACTUAL","2021-10-01","2024-05","2024-05-31","2023-06-26","ACTUAL","2023-06-26","2023-03-19","ACTUAL","2023-03-19",NA,"INTERVENTIONAL",NA,"Adult trauma in-patients with three or more rib fractures. Inclusion criteria were: age \>18 years, known blunt chest trauma with \>three rib fractures, and able to provide informed consent.","Low Dose Ketamine for Blunt Thoracic Trauma","Low Dose Ketamine for Blunt Thoracic Trauma: A Prospective Randomized Trial","COMPLETED",NA,"PHASE4",50,"ACTUAL","North Memorial Health Care",NA,2,NA,NA,"f",NA,NA,NA,"f","t","f",NA,NA,"t",NA,NA,NA,NA,NA,"NO",NA,"2024-09-15 12:24:53.847654","2024-09-15 12:24:53.847654","OTHER",NA,NA,NA,NA,NA,NA
"NCT01933880",NA,"2013-08-28","2013-11-25",NA,"2014-09-16","2013-08-28","2013-09-02","ESTIMATED","2014-09-16","2014-09-17","ESTIMATED",NA,NA,NA,"2014-09-16","2014-09-17","ESTIMATED","2009-12",NA,"2009-12-31","2014-09","2014-09-30","2010-11","ACTUAL","2010-11-30","2010-11","ACTUAL","2010-11-30",NA,"INTERVENTIONAL",NA,"Full Analysis Set (FAS) includes all of the subjects who received at least one study drug therapy and at least one efficacy evaluation. FAS for normal group included all participants who received baseline assessment scale evaluation and had at least one endpoint assessment scale evaluation.","A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants","An Open, Self-Controlled, Prospective Study of Concerta on Cognitive Functions, Efficacy and Tolerance in the Pediatric Patients With Attention Deficit Hyperactivity Disorder (ADHD)","COMPLETED",NA,"PHASE4",194,"ACTUAL","Xian-Janssen Pharmaceutical Ltd.",NA,2,NA,NA,"f",NA,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-16 11:36:05.560137","2024-09-16 11:36:05.560137","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT01766050",NA,"2013-01-10","2014-04-28",NA,"2014-05-27","2013-01-10","2013-01-11","ESTIMATED","2014-05-27","2014-06-27","ESTIMATED",NA,NA,NA,"2014-05-27","2014-06-27","ESTIMATED","2013-01",NA,"2013-01-31","2014-05","2014-05-31","2013-04","ACTUAL","2013-04-30","2013-04","ACTUAL","2013-04-30",NA,"INTERVENTIONAL",NA,"All participants who received study drug.","Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers","An Open-label, Single-sequence Study of the Effect of Belatacept on the Pharmacokinetics of Caffeine, Losartan, Omeprazole, Dextromethorphan, and Midazolam Administered as Inje Cocktail in Healthy Subjects","COMPLETED",NA,"PHASE4",45,"ACTUAL","Bristol-Myers Squibb",NA,1,NA,NA,"f",NA,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-15 23:33:55.825213","2024-09-15 23:33:55.825213","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT02413918",NA,"2015-04-07","2015-04-21",NA,"2018-01-12","2015-04-09","2015-04-10","ESTIMATED","2017-10-05","2017-11-06","ACTUAL",NA,NA,NA,"2018-01-12","2018-02-08","ACTUAL","2012-04",NA,"2012-04-30","2017-05","2017-05-31","2015-04","ACTUAL","2015-04-30","2015-04","ACTUAL","2015-04-30",NA,"INTERVENTIONAL",NA,"Subject meeting inclusion criteria","Iloperidone in Mixed States of Bipolar Disorder","Open Label Study of Iloperidone (IL) as Adjunctive Treatment in Mixed States (MS) of Bipolar Disorder (BD)","COMPLETED",NA,"PHASE4",41,"ACTUAL","The University of Texas Health Science Center at San Antonio",NA,1,NA,NA,"f",NA,NA,NA,"t",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-15 23:33:55.825213","2024-09-15 23:33:55.825213","OTHER",NA,NA,NA,NA,NA,NA
"NCT03624881",NA,"2018-07-26","2022-06-28",NA,"2023-06-28","2018-08-07","2018-08-10","ACTUAL","2022-08-15","2022-09-07","ACTUAL",NA,NA,NA,"2023-06-28","2023-07-03","ACTUAL","2018-09-04","ACTUAL","2018-09-04","2023-06","2023-06-30","2021-06-28","ACTUAL","2021-06-28","2021-06-28","ACTUAL","2021-06-28",NA,"INTERVENTIONAL",NA,"The safety set consisted of all enrolled participants who had undergone insertion of the STSF or ST catheter and use of the VISITAG SURPOINT module with EPU.","Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)","Evaluation of the VISITAG SURPOINT™ Module With External Processing Unit (EPU) When Used With the THERMOCOOL SMARTTOUCH® SF and the THERMOCOOL SMARTTOUCH® Catheters for Pulmonary Vein Isolation (PVI) (SURPOINT COA)","COMPLETED",NA,"PHASE4",333,"ACTUAL","Biosense Webster, Inc.",NA,1,NA,NA,"f",NA,NA,NA,"f","f","t",NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,"2024-09-15 23:33:55.825213","2024-09-15 23:33:55.825213","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT03796728",NA,"2018-12-17","2021-06-09",NA,"2021-07-09","2019-01-07","2019-01-08","ACTUAL","2021-07-09","2021-07-28","ACTUAL",NA,NA,NA,"2021-07-09","2021-07-28","ACTUAL","2018-12-19","ACTUAL","2018-12-19","2021-07","2021-07-31","2020-06-09","ACTUAL","2020-06-09","2020-06-09","ACTUAL","2020-06-09",NA,"INTERVENTIONAL","LIPS","Safety Analysis Set included all participants who were consented and enrolled into this study and were treated with the investigational product Juvéderm® VOLIFT™ with Lidocaine.","A Study to Evaluate the Effectiveness of Juvéderm® VOLIFT™ With Lidocaine for Lip Augmentation","LIPS: A Prospective, Open-label Study to Evaluate the Effectiveness of Juvéderm® VOLIFT™ With Lidocaine for Lip Augmentation","COMPLETED",NA,"PHASE4",60,"ACTUAL","Allergan",NA,1,NA,NA,"f",NA,NA,NA,NA,"f","f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-15 23:39:50.689837","2024-09-15 23:39:50.689837","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT03066622",NA,"2016-12-06","2019-07-03",NA,"2022-01-02","2017-02-23","2017-02-28","ACTUAL","2019-08-01","2019-08-20","ACTUAL",NA,NA,NA,"2022-01-02","2022-01-12","ACTUAL","2016-07","ACTUAL","2016-07-31","2018-06","2018-06-30","2018-05-20","ACTUAL","2018-05-20","2018-05-17","ACTUAL","2018-05-17",NA,"INTERVENTIONAL","Olanzapine","The baseline population included is 119 as 5 subjects withdrew after providing informed consent.","Olanzapine for Acute Headaches","Oral Rapidly Dissolving Olanzapine for Acute Primary Headache in the Emergency Department Setting: A Feasibility Trial","COMPLETED",NA,"PHASE4",122,"ACTUAL","HealthPartners Institute",NA,2,NA,NA,"f",NA,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"NO",NA,"2024-09-16 11:42:54.02049","2024-09-16 11:42:54.02049","OTHER",NA,NA,NA,NA,NA,NA
"NCT00781768",NA,"2008-10-27","2017-12-14",NA,"2018-06-29","2008-10-28","2008-10-29","ESTIMATED","2018-06-29","2018-07-27","ACTUAL",NA,NA,NA,"2018-06-29","2018-07-27","ACTUAL","2003-08",NA,"2003-08-31","2018-06","2018-06-30","2010-07","ACTUAL","2010-07-31","2008-10","ACTUAL","2008-10-31",NA,"INTERVENTIONAL",NA,"Autologous and allogeneic hematopoietic stem cell transplant patients.","Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea","Prevention of Nausea and Vomitting Associated With Stem Cell Transplant: Results of a Prospective, Randomized Trial of Aprepitant Used With Highly Emetogenic Preparative Regimens","COMPLETED",NA,"PHASE4",181,"ACTUAL","Loyola University","There are no limitations or caveats to disclose.",2,NA,NA,"f",NA,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-15 23:39:50.689837","2024-09-15 23:39:50.689837","OTHER",NA,NA,NA,NA,NA,NA
"NCT02891174",NA,"2016-08-26","2019-03-19",NA,"2019-05-03","2016-08-31","2016-09-07","ESTIMATED","2019-05-03","2019-05-23","ACTUAL",NA,NA,NA,"2019-05-03","2019-05-23","ACTUAL","2016-12-01","ACTUAL","2016-12-01","2019-05","2019-05-31","2018-06-20","ACTUAL","2018-06-20","2018-03-31","ACTUAL","2018-03-31",NA,"INTERVENTIONAL",NA,"Baseline characteristics were measured after the first milestone, after 6 total participants who were initially randomized declined the study medication.","The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy","A Randomized-controlled Trial to Assess the Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy","COMPLETED",NA,"PHASE4",74,"ACTUAL","University of Michigan",NA,2,NA,NA,"f",NA,NA,NA,"f","t","f",NA,NA,"f",NA,NA,NA,NA,NA,"NO",NA,"2024-09-15 23:46:20.200255","2024-09-15 23:46:20.200255","OTHER",NA,NA,NA,NA,NA,NA
"NCT02714400",NA,"2016-02-26","2020-03-23",NA,"2020-04-07","2016-03-15","2016-03-21","ESTIMATED","2020-04-07","2020-04-17","ACTUAL",NA,NA,NA,"2020-04-07","2020-04-17","ACTUAL","2016-03","ACTUAL","2016-03-31","2020-04","2020-04-30","2016-07","ACTUAL","2016-07-31","2016-07","ACTUAL","2016-07-31",NA,"INTERVENTIONAL",NA,"Age 35-64 years","The Impact of Venlafaxine on Apnea Hypopnea Index in Obstructive Sleep Apnea","The Impact of Venlafaxine on Apnea Hypopnea Index in Patients With Obstructive Sleep Apnea","COMPLETED",NA,"PHASE4",20,"ACTUAL","University of California, San Diego",NA,2,NA,NA,"f",NA,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-15 23:46:20.200255","2024-09-15 23:46:20.200255","OTHER",NA,NA,NA,NA,NA,NA
"NCT03305666",NA,"2017-10-04","2021-07-08",NA,"2021-09-02","2017-10-06","2017-10-10","ACTUAL","2021-08-02","2021-08-25","ACTUAL",NA,NA,NA,"2021-09-02","2021-09-29","ACTUAL","2017-10-05","ACTUAL","2017-10-05","2021-09","2021-09-30","2021-01-31","ACTUAL","2021-01-31","2020-07-20","ACTUAL","2020-07-20",NA,"INTERVENTIONAL",NA,"The baseline analysis did not include two patients who were withdrawn from the study.","Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures","A Randomized Clinical Trial of Single Dose Liposomal Bupivacaine Delivered Via VATS Intercostal Nerve Block vs. Continuous Bupivacaine Infusion Delivered Via Indwelling Subscapular Catheter After Surgical Stabilization of Rib Fractures","COMPLETED",NA,"PHASE4",36,"ACTUAL","Denver Health and Hospital Authority","There were no limitations that created barriers to the completion of this project. While this was expected at the outset of this exploratory trial, there was a relatively small sample size with a wide range of fractures for individual participants. Underpowering likely limited analyses of secondary outcomes such as narcotic requirements and failure of LRA. The study also excluded patients with GCS \< 8, so caution should be exercised when extrapolating to mechanically ventilated patients.",2,NA,NA,"f",NA,NA,NA,"t","t","f",NA,NA,"t",NA,NA,NA,NA,NA,"NO",NA,"2024-09-15 23:46:20.200255","2024-09-15 23:46:20.200255","OTHER",NA,NA,NA,NA,NA,NA
"NCT01396395",NA,"2011-07-15","2015-09-14",NA,"2016-03-15","2011-07-15","2011-07-18","ESTIMATED","2016-03-15","2016-04-14","ESTIMATED",NA,NA,NA,"2016-03-15","2016-04-14","ESTIMATED","2011-09",NA,"2011-09-30","2016-03","2016-03-31","2014-05","ACTUAL","2014-05-31","2014-05","ACTUAL","2014-05-31",NA,"INTERVENTIONAL","SIGMART","Full analysis set (FAS) included all randomized subjects who received at least one dose of study treatment.","Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina","A Prospective, Multi-center, Random, Open-label Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina","COMPLETED",NA,"PHASE4",402,"ACTUAL","Merck KGaA, Darmstadt, Germany",NA,2,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-16 11:42:54.02049","2024-09-16 11:42:54.02049","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT01650519",NA,"2012-07-24","2014-04-15",NA,"2016-05-17","2012-07-24","2012-07-26","ESTIMATED","2014-07-08","2014-07-10","ESTIMATED",NA,NA,NA,"2016-05-17","2016-06-23","ESTIMATED","2012-09",NA,"2012-09-30","2016-05","2016-05-31","2013-01","ACTUAL","2013-01-31","2012-12","ACTUAL","2012-12-31",NA,"INTERVENTIONAL",NA,"The Intent-to-treat population consists of all patients who received at least a partial dose of study medication.","A Pilot Study to Determine the Efficacy of Intravenous Ibuprofen for Pain Control Following Arthroscopic Knee Surgery","A Pilot Study to Determine the Efficacy of Intravenous Ibuprofen for Pain Control Following Arthroscopic Knee Surgery","COMPLETED",NA,"PHASE4",51,"ACTUAL","Cumberland Pharmaceuticals",NA,2,NA,NA,"f",NA,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-16 11:42:54.02049","2024-09-16 11:42:54.02049","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT01644734",NA,"2012-07-17","2014-03-28",NA,"2014-04-30","2012-07-18","2012-07-19","ESTIMATED","2014-04-30","2014-05-26","ESTIMATED",NA,NA,NA,"2014-04-30","2014-05-26","ESTIMATED","2011-11",NA,"2011-11-30","2014-04","2014-04-30","2013-03","ACTUAL","2013-03-31","2013-03","ACTUAL","2013-03-31",NA,"INTERVENTIONAL",NA,"Patients from the Treated Set (TS) which are dispensed study medication and were documented to have taken at least one dose of investigational treatment.","Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test","MATHS: Assessment of Health-status of Patients With COPD on MAintenance THerapy With Spiriva® HH Measured by CAT Test","COMPLETED",NA,"PHASE4",1328,"ACTUAL","Boehringer Ingelheim",NA,NA,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-16 11:42:54.02049","2024-09-16 11:42:54.02049","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT00717314",NA,"2008-07-16","2014-06-04",NA,"2014-09-23","2008-07-16","2008-07-17","ESTIMATED","2014-09-23","2014-09-29","ESTIMATED",NA,NA,NA,"2014-09-23","2014-09-29","ESTIMATED","2008-05",NA,"2008-05-31","2014-09","2014-09-30","2011-07","ACTUAL","2011-07-31","2011-07","ACTUAL","2011-07-31",NA,"INTERVENTIONAL",NA,"Per-Protocol (PP) population: all participants who received at least 1 dose of the treatment-group specific medication who did not dropout from the study prematurely.","A Study of CellCept (Mycophenolate Mofetil) Combined With Calcineurin Inhibitors in Liver Transplant Patients.","A Randomized, Open Label Study Comparing the Effect of CellCept Combined With 2 Regimens of Reduced Calcineurin Inhibitors on Kidney Function in Liver Transplant Patients","COMPLETED",NA,"PHASE4",87,"ACTUAL","Hoffmann-La Roche",NA,2,NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-16 11:49:05.022065","2024-09-16 11:49:05.022065","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT01741454",NA,"2012-11-29","2019-02-25",NA,"2019-06-20","2012-11-30","2012-12-05","ESTIMATED","2019-06-20","2019-07-10","ACTUAL",NA,NA,NA,"2019-06-20","2019-07-10","ACTUAL","2012-11",NA,"2012-11-30","2019-06","2019-06-30","2018-03-30","ACTUAL","2018-03-30","2018-03-30","ACTUAL","2018-03-30",NA,"INTERVENTIONAL",NA,"Patients who dropped out were not analyzed","Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction","Combination Versus Monotherapy With Alpha Blocker and Anticholinergics to Relieve Urinary Stent Symptoms","COMPLETED",NA,"PHASE4",181,"ACTUAL","University of Wisconsin, Madison",NA,4,NA,NA,"f",NA,NA,NA,"f","t","f",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-16 11:49:05.022065","2024-09-16 11:49:05.022065","OTHER",NA,NA,NA,NA,NA,NA
"NCT00744263",NA,"2008-08-27","2014-10-01",NA,"2014-10-01","2008-08-28","2008-08-29","ESTIMATED","2014-10-01","2014-10-06","ESTIMATED",NA,NA,NA,"2014-10-01","2014-10-06","ESTIMATED","2008-09",NA,"2008-09-30","2014-10","2014-10-31","2013-10","ACTUAL","2013-10-31","2013-10","ACTUAL","2013-10-31",NA,"INTERVENTIONAL","CAPITA","Safety population included all participants who received study vaccine and who had any safety data.","Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults","A Phase 4, Randomized, Placebo-Controlled Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine Efficacy in Prevention of Vaccine-Serotype Pneumococcal Community-Acquired Pneumonia and Invasive Pneumococcal Disease","COMPLETED",NA,"PHASE4",84496,"ACTUAL","Pfizer",NA,2,NA,NA,"f",NA,NA,NA,"t",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2024-09-16 11:49:05.022065","2024-09-16 11:49:05.022065","INDUSTRY",NA,NA,NA,NA,NA,NA
"NCT01521117",NA,"2012-01-12","2021-08-02",NA,"2021-09-09","2012-01-25","2012-01-30","ESTIMATED","2021-08-02","2021-08-27","ACTUAL",NA,NA,NA,"2021-09-09","2021-10-05","ACTUAL","2011-12",NA,"2011-12-31","2021-09","2021-09-30","2012-07","ACTUAL","2012-07-31","2012-04","ACTUAL","2012-04-30",NA,"INTERVENTIONAL",NA,"Baseline characteristics are reported on all study completers (N = 10).","The Effect of Donepezil on Gait and Balance in Parkinson's Disease","A Randomized, Double-blind, Placebo Controlled, Crossover Study to Evaluate the Effect of Donepezil on Gait and Balance in Parkinson's Disease","COMPLETED",NA,"PHASE4",21,"ACTUAL","Oregon Health and Science University",NA,2,NA,NA,"f",NA,NA,NA,"t","t","f",NA,NA,"f",NA,NA,NA,NA,NA,NA,NA,"2024-09-15 23:52:50.854359","2024-09-15 23:52:50.854359","OTHER",NA,NA,NA,NA,NA,NA
